United States Adrenocortical Hormones API Market Analysis 2024-2031: Forecast to Reach USD 2.8 Billion, with Glucocorticoids Driving 30% Share

Market Size & Growth

The global adrenocortical hormones API market is witnessing steady growth, driven by increasing prevalence of endocrine disorders, rising geriatric population, and expanding use of corticosteroids and mineralocorticoids across therapeutic applications. The market was valued at approximately USD 1.8 billion in 2023 and is projected to reach around USD 2.8 billion by 2031, growing at a CAGR of 5.8% during the forecast period. The rising demand for high-purity active pharmaceutical ingredients (APIs) and development of novel corticosteroid therapies are further enhancing adoption across hospitals, clinics, and pharmaceutical manufacturers.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/adrenocortical-hormones-api-market?Juli

Adrenocortical hormones APIs are pharmaceutical-grade active ingredients used in the production of glucocorticoids, mineralocorticoids, and corticosteroid formulations for treating inflammation, autoimmune disorders, and adrenal insufficiency.

Recent Developments:
United States
✅ March 2025: Pfizer CentreOne launched high-purity glucocorticoid APIs for injectable and oral formulations, contributing approximately USD 25 million in market value.

✅ June 2025: Sanofi expanded production capacity for hydrocortisone and betamethasone APIs, generating an incremental revenue of around USD 18 million.

✅ September 2025: Research initiatives developed modified-release mineralocorticoid APIs, adding nearly USD 12 million to the U.S. market.

Japan
✅ February 2025: Japanese pharmaceutical firms introduced advanced fludrocortisone APIs for adrenal insufficiency treatments, contributing USD 8 million to regional growth.

✅ May 2025: Development of novel topical corticosteroid APIs enhanced local dermatology applications, generating approximately USD 5 million in new revenue.

✅ August 2025: Collaborations launched betamethasone API formulations with improved bioavailability, supporting an additional USD 4 million in market value.

Market Segmentation:
By Type:
Glucocorticoids hold 30%, used widely in anti-inflammatory and immunosuppressive therapies. Betamethasone contributes 20%, primarily in injectable and topical formulations. Hydrocortisone accounts for 18%, favored for adrenal insufficiency and dermatological applications. Mineralocorticoids represent 12%, mainly for electrolyte balance therapies. Fludrocortisone holds 10%, used in chronic adrenal insufficiency treatments.

By Route of Administration:
Injectable drugs account for 35%, preferred for rapid onset in hospital and emergency use.

Oral drugs represent 30%, widely adopted for chronic therapies.
For external use drugs hold 20%, mainly in dermatology and topical applications. Inhalation drugs account for 15%, targeting respiratory inflammation and asthma treatment.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=adrenocortical-hormones-api-market?Juli

Competitive Landscape:

The market is moderately consolidated, with leading players focusing on capacity expansion, strategic partnerships, and high-purity API development. Key players include:

Sanofi: holds 15% of the global market, specializing in glucocorticoid and hydrocortisone APIs.

Pfizer CentreOne: contributes 12%, focusing on injectable corticosteroid APIs.

GlaxoSmithKline (GSK): around 10%, offering a broad range of adrenocortical hormone APIs.

Symbiotec Pharmalab: 8%, emphasizing high-purity oral APIs.

Sun Pharmaceutical & Cipla: 7% each, serving oral and topical formulations.

Hovione, Teva Pharmaceuticals Pvt Ltd, Tianjin Pharmaceutical Group Co. Ltd, Great Pacific Exports collectively 15%, focusing on regional distribution and contract manufacturing.

➠Market Drivers:
Key drivers include rising prevalence of autoimmune and inflammatory disorders, increasing global geriatric population, and growing adoption of corticosteroids in chronic disease management. Enhanced R&D in synthetic and high-purity APIs, coupled with expansion of pharmaceutical manufacturing capacities, supports steady market growth. Moreover, government approvals and regulatory support for steroidal therapies further drive adoption across hospital, clinic, and pharmaceutical applications.

Mergers & Acquisitions:
The market has witnessed strategic acquisitions, joint ventures, and partnerships to expand product portfolios, enhance R&D capabilities, and improve global distribution networks. These initiatives help companies introduce novel corticosteroid APIs, optimize production efficiency, and consolidate their position in the competitive adrenocortical hormone segment.

Get Customized Report as per your Business Requirements: https://www.datamintelligence.com/customize/adrenocortical-hormones-api-market?Juli

Regional Insights:
North America dominates the market with approximately 40%, driven by advanced pharmaceutical manufacturing infrastructure, strong R&D investment, and high demand for injectable and oral corticosteroid therapies. The U.S. contributes the largest share, supported by widespread hospital adoption and regulatory approvals for innovative APIs.

Europe accounts for around 30%, backed by established healthcare systems, government support for chronic disease management, and adoption of high-purity steroidal APIs in countries like Germany, France, and the UK.

Asia-Pacific represents 20%, led by Japan, China, and India, where growing healthcare expenditure, rising prevalence of autoimmune diseases, and expanding pharmaceutical manufacturing capabilities drive market growth.

Latin America and the Middle East & Africa (MEA) collectively hold 10%, reflecting gradual adoption driven by increasing healthcare access, regulatory frameworks, and expansion of hospital and clinical infrastructure.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.